The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Abstract
PURPOSE: Breast cancer frequently overexpresses the product of the HER2 proto-oncogene, a 185-kd growth factor receptor (p185HER2). The recombinant humanized monoclonal antibody (rhuMAb) HER2 has high affinity for p185HER2 and inhibits the growth of breast cancer cells that overexpress HER2. We evaluated the efficacy and toxicity of weekly intravenous administration of rhuMAb HER2 in patients with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: We treated 46 patients with metastatic breast carcinomas that overexpressed HER2. Patients received a loading dose of 250 mg of intravenous rhuMAb HER2, then 10 weekly doses of 100 mg each. Patients with no disease progression at the completion of this treatment period were offered a maintenance phase of 100 mg/wk. RESULTS: Study patients had extensive metastatic disease, and most had received extensive prior anticancer therapy. Adequate pharmacokinetic levels of rhuMAb HER2 were obtained in 90% of the patients. Toxicity was minimal and no antibodies against rhuMAb HER2 were detected in any patients. Objective responses were seen in five of 43 assessable patients, and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% confidence interval, 4.36 to 25.9). Responses were observed in liver, mediastinum, lymph nodes, and chest wall lesions. Minor responses, seen in two patients, and stable disease, which occurred in 14 patients, lasted for a median of 5.1 months. CONCLUSION: rhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy. This is evidence that targeting growth factor receptors can cause regression of human cancer and justifies further evaluation of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Riethmüller, G., Gruber, R., Schneider-Gädicke, E., Schlimok, G., Witte, J., Raab, R., Pichlmayr, R., Pichlmaier, H., Schmiegel, W., Buggisch, P., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92398-1 · Cited by 633
Hudziak, R. M., Schlessinger, J., & Ullrich, A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7159 · Cited by 625
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Self-citationPietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 400
Stern, D. F., Heffernan, P. A., & Weinberg, R. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1729 · Cited by 327
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 254
Hancock, M. C., Langton-Webster, B. C., Chan, T., Toy, P., Monahan, J., Mischak, R. P., & Shawver, L. K. (1991) · PubMed · Cited by 225
Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., & Sela, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8691 · Cited by 203
Zabrecky, J. R., Lam, T., McKenzie, S. J., & Carney, W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52354-1 · Cited by 201
Scott, G. K., Robles, R., Park, J. W., Montgomery, P. A., Daniel, J., Holmes, W. E., Lee, J., Keller, G. A., Li, W. L., & Fendly, B. M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.4.2247 · Cited by 158
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
Harwerth, I. M., Wels, W. S., Schlegel, J., Müller, M., & Ne, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.494 · Cited by 114
p185HER2 signal transduction in breast cancer cells
Scott, G. K., Dodson, J. M., Montgomery, P. A., Johnson, R. M., Sarup, J. C., Wong, W., Ullrich, A., Shepard, H. M., & Benz, C. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98683-7 · Cited by 87
Self-citationELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M., & Wong, W. L. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90400-p · Cited by 34
Cited by
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
“analyzed (%) «1 48/143 (34) 49/136 (36) 31/91 (34) 27/95 (28) 2 38/143 (27) 48/136 (35) 32/91 (35) 35/95 (37) »3 57/143 (40) 39/136 (29) 28/91 (31) 33/95 (35)”
Self-citationUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
“(Abl, a proto-oncogenic tyrosine kinase whose targets are poorly understood; Akt, a serine/threonine kinase that phosphorylates the anti-apoptotic protein Bad and the ribosomal S6 kinase (S6K); GAP, GTPase activating protein; HB-EGF, heparin-binding EGF; Jak, janus kinase; PKC, protein kinase C; PLCγ, phospholipase Cγ…”
InfluentialTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Self-citationTrastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Self-citation
Metadata
- Authors
- Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 737-744
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2222638000
- Cited by
- 1,380
- References
- 28
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.